HISTORICAL GAAP P&L TREND - CONSOLIDATED ($000's)

	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Revenues:													
Revenue from products and services	108,242	29,070	28,834	40,052	43,123	141,079	43,716	61,885	62,735	73,922	242,258	70,918	84,151
Revenue from Int'l supply agreement	5,185	1,045	795	1,111	831	3,782	405	364	145	40	954	15	-
TOTAL REVENUE	**113,427**	**30,115**	**29,629**	**41,163**	**43,954**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**
Cost of revenue	35,833	9,084	8,787	11,926	12,563	42,360	12,263	21,184	23,266	28,737	85,450	21,717	28,675
Total gross profit	**77,594**	**21,031**	**20,842**	**29,237**	**31,391**	**102,501**	**31,858**	**41,065**	**39,614**	**45,225**	**157,762**	**49,216**	**55,476**
Operating expenses (GAAP):													
Research & development	15,486	4,169	4,237	4,984	5,355	18,745	5,801	7,839	9,391	8,984	32,015	9,722	10,596
Sales, general & administrative	100,077	27,583	26,468	35,380	39,725	129,156	40,426	60,659	61,494	66,692	229,271	69,471	72,668
Litigation-related	8,549	2,643	1,304	1,560	3,045	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495
Amortization of acquired intangible assets	698	172	172	172	172	688	172	1,208	2,012	1,956	5,348	2,230	2,177
Transaction-related expenses	-	4,272	(181)	2	130	4,223	1,012	4,771	373	209	6,365	120	-
Restructuring expenses	60	-	-	-	-	-	158	1,173	256	110	1,697	1,370	289
Gain on Settlement	-	-	-	-	-	-	-	-	-	-	-	-	-
Total operating expenses (GAAP)	**124,870**	**38,839**	**32,000**	**42,098**	**48,427**	**161,364**	**50,904**	**76,817**	**74,735**	**83,363**	**285,819**	**90,445**	**91,225**
TOTAL OPERATING LOSS	**(47,276)**	**(17,808)**	**(11,158)**	**(12,861)**	**(17,036)**	**(58,863)**	**(19,046)**	**(35,752)**	**(35,121)**	**(38,138)**	**(128,057)**	**(41,229)**	**(35,749)**
Other income (expense):													
Interest and other income (expense),net	(9,865)	(2,874)	(3,032)	(2,768)	(3,700)	(12,374)	(3,827)	(2,410)	(386)	(2,048)	(8,671)	(1,486)	(1,368)
Loss on debt extinguishment	-	-	(1,555)	-	(6,057)	(7,612)	-	-	(7,434)	-	(7,434)	-	-
Gain on change in fair value of warrants	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income (expense), net	**(9,865)**	**(2,874)**	**(4,587)**	**(2,768)**	**(9,757)**	**(19,986)**	**(3,827)**	**(2,410)**	**(7,820)**	**(2,048)**	**(16,105)**	**(1,486)**	**(1,368)**
Income (loss) from continuing operations (GAAP)	**(57,141)**	**(20,682)**	**(15,745)**	**(15,629)**	**(26,793)**	**(78,849)**	**(22,873)**	**(38,162)**	**(42,941)**	**(40,186)**	**(144,162)**	**(42,715)**	**(37,117)**
Income tax provision	(239)	40	60	40	5	145	30	43	90	1	164	129	203
Net loss from continuing operations	**(56,902)**	**(20,722)**	**(15,805)**	**(15,669)**	**(26,798)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**
Income (Loss) from discontinued operations	(100)	-	-	-	-	-	-	-	-	-	-	-	-
Net loss	**(57,002)**	**(20,722)**	**(15,805)**	**(15,669)**	**(26,798)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**
Recognition of beneficial conversion feature - Series B preferred stock	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss attributable to common shareholders	**(57,002)**	**(20,722)**	**(15,805)**	**(15,669)**	**(26,798)**	**(78,994)**	**(22,903)**	**(38,205)**	**(43,031)**	**(40,187)**	**(144,326)**	**(42,844)**	**(37,320)**
Net loss per share	**(1.09)**	**(0.33)**	**(0.25)**	**(0.24)**	**(0.35)**	**(1.18)**	**(0.26)**	**(0.39)**	**(0.43)**	**(0.40)**	**(1.50)**	**(0.43)**	**(0.36)**
Weighted avg shares outstanding, basic and diluted	**52,234**	**62,568**	**63,713**	**64,761**	**77,098**	**67,020**	**87,223**	**98,541**	**99,571**	**99,300**	**96,197**	**99,978**	**102,849**

GUIDANCE / COMMENTARY

FY 2022 total revenue is expected to approximate $325M, which includes ~$48M of EOS-related revenue. The int'l supply agreement terminated Aug 2021.

PROFORMA GAAP P&L - EOS ($)

	Q120	Q220	Q320	Q420	2020*	Q121*	Q221*
Revenues:							
Revenue from products and servic	4,096	6,685	7,389	9,021	27,191	6,865	7,945
TOTAL REVENUE	**4,096**	**6,685**	**7,389**	**9,021**	**27,191**	**6,865**	**7,945**
Cost of revenue					26,488	3,716	5,482
Total gross profit					**703**	**3,149**	**2,463**
Operating expenses (GAAP):							
Research & development					4,690	985	2,213
Sales, general & administrative					14,285	4,503	3,893
Litigation-related					-	-	-
Amortization of acquired intangible assets					7,124	1,796	1,979
Transaction-related expenses					10,298	-	-
Restructuring expenses					-	-	-
Gain on Settlement					-	-	-
Total operating expenses (GAAP)					**36,397**	**7,284**	**8,085**
TOTAL OPERATING LOSS					**(35,694)**	**(4,135)**	**(5,622)**
Other income (expense):							
Interest and other income (expense),net					300	(116)	(236)
Loss on debt extinguishment					-	-	-
Total other income (expense), net					300	**(116)**	**(236)**
Loss from continuing operations before taxes					**(35,394)**	**(4,251)**	**(5,858)**
Income tax provision (benefit)					89	18	(18)
Net loss					**(35,483)**	**(4,269)**	**(5,840)**

Data as of Q2 2022 earnings release on August 4, 2022. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.

atec INFORMED BY EOS — NON-GAAP RECONCILIATION - CONSOLIDATED ($000's)

ADJUSTED EBITDA	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Operating loss, GAAP	(47,276)	(17,808)	(11,158)	(12,861)	(17,036)	(58,863)	(19,046)	(35,752)	(35,121)	(38,138)	(128,057)	(41,229)	(35,749)
Depreciation	6,775	2,014	2,161	2,307	2,704	9,186	3,409	5,068	5,311	6,544	20,332	7,085	7,506
Amortization of intangible assets	803	440	440	442	441	1,763	441	1,476	2,281	2,226	6,424	2,230	2,186
Total EBITDA	**(39,698)**	**(15,354)**	**(8,557)**	**(10,112)**	**(13,891)**	**(47,914)**	**(15,196)**	**(29,208)**	**(27,529)**	**(29,368)**	**(101,301)**	**(31,914)**	**(26,057)**
+ Stock-based compensation	10,954	3,568	4,575	4,544	4,972	17,659	4,474	11,496	10,754	9,726	36,450	10,184	9,203
+ Purchase accounting adjustments on acquisitions	-	-	-	-	-	-	-	1,763	2,577	2,083	6,423	-	437
+ Excess & obsolete charges	8,624	1,722	1,712	1,995	1,615	7,044	2,096	2,221	2,525	4,305	11,147	1,706	2,394
+ Contingent consideration fair value adjustment	289	-	-	-	-	-	-	-	-	-	-	-	-
+ Litigation-related expenses	8,549	2,643	1,304	1,560	3,045	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495
+ Transaction-related expenses	-	4,272	(181)	2	130	4,223	1,012	4,771	373	209	6,365	120	-
+ Restructuring expenses	60	-	-	-	-	-	158	1,173	256	110	1,697	1,370	289
+ Gain on settlement	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Adjusted EBITDA	**(11,222)**	**(3,149)**	**(1,147)**	**(2,011)**	**(4,129)**	**(10,436)**	**(4,121)**	**(6,617)**	**(9,835)**	**(7,523)**	**(28,096)**	**(11,002)**	**(8,239)**
Adjusted EBITDA as a % of Revenue	***-9.9%***	***-10.5%***	***-3.9%***	***-4.9%***	***-9.4%***	***-7.2%***	***-9.3%***	***-10.6%***	***-15.6%***	***-10.2%***	***-11.6%***	***-15.5%***	***-9.8%***

Adjusted EBITDA % for the full year 2022 is expected to improve 400bps relative to full year 2021.

NON-GAAP GROSS PROFIT & GROSS MARGIN	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Gross Profit, GAAP	77,594	21,031	20,842	29,237	31,391	102,501	31,858	41,065	39,614	45,225	157,762	49,216	55,476
+ Amortization of intangible assets	105	268	268	270	269	1,075	269	268	270	268	1,075	-	9
+ Stock-based compensation	146	107	128	139	138	512	95	84	310	248	737	256	449
+ Purchase accounting adjs on acquisitions	-	-	-	-	-	-	-	1,763	2,577	2,083	6,423	-	437
+ Excess & obsolescence charges	8,624	1,722	1,712	1,995	1,615	7,044	2,096	2,221	2,525	4,305	11,147	1,706	2,394
Non-GAAP Gross Profit	**86,469**	**23,128**	**22,950**	**31,641**	**33,413**	**111,132**	**34,318**	**45,401**	**45,296**	**52,129**	**177,144**	**51,178**	**58,765**
Gross Margin, GAAP	**68.4%**	**69.8%**	**70.3%**	**71.0%**	**71.4%**	**70.8%**	**72.2%**	**66.0%**	**63.0%**	**61.1%**	**64.9%**	**69.4%**	**65.9%**
+ Amortization of intangible assets	0.1%	0.9%	0.9%	0.7%	0.6%	0.7%	0.6%	0.4%	0.4%	0.4%	0.4%	0.0%	0.0%
+ Stock-based compensation	0.1%	0.4%	0.4%	0.3%	0.3%	0.4%	0.2%	0.1%	0.5%	0.3%	0.3%	0.4%	0.5%
+ Purchase accounting adjs on acquisitions	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.8%	4.1%	2.8%	2.6%	0.0%	0.5%
+ Excess & obsolescence charges	7.6%	5.7%	5.8%	4.8%	3.7%	4.9%	4.8%	3.6%	4.0%	5.8%	4.6%	2.4%	2.8%
Non-GAAP Gross Margin	**76.2%**	**76.8%**	**77.5%**	**76.9%**	**76.0%**	**76.7%**	**77.8%**	**72.9%**	**72.0%**	**70.5%**	**72.8%**	**72.1%**	**69.7%**

GM% impacted by consolidation of EOS, which bears lower GMs.

NON-GAAP OPERATING EXPENSES	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Research & Development, GAAP	**15,486**	**4,169**	**4,237**	**4,984**	**5,355**	**18,745**	**5,801**	**7,839**	**9,391**	**8,984**	**32,015**	**9,722**	**10,596**
- Stock-based compensation in R&D	1,044	390	548	504	632	2,074	498	664	1,440	1,454	4,056	972	1,362
- Contingent consideration fair value adj	289	-	-	-	-	-	-	-	-	-	-	-	-
Non-GAAP R&D	**14,153**	**3,779**	**3,689**	**4,480**	**4,723**	**16,671**	**5,303**	**7,175**	**7,951**	**7,530**	**27,959**	**8,750**	**9,234**
Sales General & Administrative, GAAP	**100,077**	**27,583**	**26,468**	**35,380**	**39,725**	**129,156**	**40,426**	**60,659**	**61,494**	**66,692**	**229,271**	**69,471**	**72,668**
- Stock-based compensation in SG&A	9,764	3,071	3,899	3,901	4,202	15,073	3,881	10,748	9,004	8,024	31,657	8,956	7,392
- Purchase accounting adjs on acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-GAAP SG&A	**90,313**	**24,512**	**22,569**	**31,479**	**35,523**	**114,083**	**36,545**	**49,911**	**52,490**	**58,668**	**197,614**	**60,515**	**65,276**
Other Operating Expense, GAAP	**9,307**	**7,087**	**1,295**	**1,734**	**3,347**	**13,463**	**4,677**	**8,319**	**3,850**	**7,687**	**24,533**	**11,252**	**7,961**
- Litigation-related expenses	8,549	2,643	1,304	1,560	3,045	8,552	3,335	1,167	1,209	5,412	11,123	7,532	5,495
- Amortization of intangible assets	698	172	172	172	172	688	172	1,208	2,012	1,956	5,348	2,230	2,177
- Transaction-related expenses	-	4,272	(181)	2	130	4,223	1,012	4,771	373	209	6,365	120	-
- Restructuring expenses	60	-	-	-	-	-	158	1,173	256	110	1,697	1,370	289
- Gain on settlement	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-GAAP Other Operating Expense	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
Total Non-GAAP Operating Expenses	**104,466**	**28,291**	**26,258**	**35,959**	**40,246**	**130,754**	**41,848**	**57,086**	**60,441**	**66,198**	**225,573**	**69,265**	**74,510**
Non-GAAP Operating Expenses % of Revenue													
Research & development	12.5%	12.5%	12.5%	10.9%	10.7%	11.5%	12.0%	11.5%	12.6%	10.2%	11.5%	12.3%	11.0%
Sales, general & administrative	79.6%	81.4%	76.2%	76.5%	80.8%	78.8%	82.8%	80.2%	83.5%	79.3%	81.3%	85.3%	77.6%
Total Non-GAAP Operating Expenses % of Revenue	**92.1%**	**93.9%**	**88.6%**	**87.4%**	**91.6%**	**90.3%**	**94.8%**	**91.7%**	**96.1%**	**89.5%**	**92.8%**	**97.6%**	**88.5%**

Opex reflects sustained levels of planned investment to support portfolio expansion and investment in the sales channel.

HISTORICAL NON-GAAP U.S. GP & GM	2019	Q120	Q220	Q320	Q420	2020	Q121
U. S. Gross Margin, GAAP	**77,235**	20,954	20,834	29,178	31,483	**102,449**	31,975
+ Excess & obsolescence charges	8,624	1,722	1,712	1,995	1,615	7,044	2,096
Non-GAAP U.S. Gross Margin	**85,859**	**22,676**	**22,546**	**31,173**	**33,098**	**109,493**	**34,071**
U.S. Gross Margin, GAAP	**71.4%**	**72.1%**	**72.3%**	**72.9%**	**73.0%**	**72.6%**	**73.1%**
+ Excess & obsolescence charges	8.0%	5.9%	5.9%	5.0%	3.7%	5.0%	4.8%
Non-GAAP U.S. Gross Margin	**79.3%**	**78.0%**	**78.2%**	**77.8%**	**76.8%**	**77.6%**	**77.9%**

EOS imaging — NON-GAAP RECONCILIATION - EOS($)

ADJUSTED EBITDA	Q120	Q220	Q320	Q420	2020*	Q121*	Q221*
Operating loss, GAAP					#####	(4,135)	(5,622)
Depreciation					806	194	200
Amortization of intangible assets					7,124	1,796	1,979
Total EBITDA	**-**	**-**	**-**	**-**	**#####**	**(2,145)**	**(3,443)**
+ Stock-based compensation					-	-	-
+ Purchase accounting adjustmer	-	-	-	-	8,600	-	-
+ Excess & obsolete charges					-	-	-
+ Contingent consideration fair value adjustment					-	-	-
+ Litigation-related expenses					-	-	-
+ Transaction-related expenses					10,298	-	-
+ Restructuring expenses					-	-	-
+ Gain on settlement					-	-	-
Total Adjusted EBITDA	**-**	**-**	**-**	**-**	**(8,866)**	**(2,145)**	**(3,443)**
Adjusted EBITDA as a % of Revenue					**-32.6%**	**-31.2%**	**-43.3%**

NON-GAAP GROSS PROFIT & G	Q120	Q220	Q320	Q420	2020	Q121	Q221
Gross Profit, GAAP					**703**	3,149	2,463
+ Amortization of intangible assets					**-**	-	-
+ Stock-based compensation					**-**	-	-
+ Purchase accounting adjustments on acquisitions					**8,600**	-	-
+ Excess & obsolescence charges					-	-	-
Non-GAAP Gross Profit					**9,303**	**3,149**	**2,463**
Gross Margin, GAAP					**2.6%**	**45.9%**	**31.0%**
+ Amortization of intangible assets					0.0%	0.0%	0.0%
+ Stock-based compensation					0.0%	0.0%	0.0%
+ Purchase accounting adjustments on acquisitions					31.6%	0.0%	0.0%
+ Excess & obsolescence charges					0.0%	0.0%	0.0%
Non-GAAP Gross Margin					**34.2%**	**45.9%**	**31.0%**

NON-GAAP OPERATING EXPEI	Q120	Q220	Q320	Q420	2020	Q121	Q221
Research & Development, GAAP					**4,690**	**985**	**2,213**
- Stock-based compensation in R&D					-	-	-
- Contingent consideration fair value adjustment					-	-	-
Non-GAAP R&D					**4,690**	**985**	**2,213**
Sales General & Administrative, GAAP					**14,285**	**4,503**	**3,893**
- Stock-based compensation in SG&A					-	-	-
- Purchase accounting adjustments on acquisitions					-		
Non-GAAP SG&A					**14,285**	**4,503**	**3,893**
Other Operating Expense, GAAP					**17,422**	**1,796**	**1,979**
- Litigation-related expenses					-	-	-
- Amortization of intangible assets					7,124	1,796	1,979
- Transaction-related expenses					10,298	-	-
- Restructuring expenses					-	-	-
- Gain on settlement					-	-	-
Non-GAAP Other Operating Expense					**-**	**-**	**-**
Total Non-GAAP Operating Expenses					**18,975**	**5,488**	**6,106**
Non-GAAP Operating Expenses as a % of Revenue							
Research & development					17.2%	14.3%	27.9%
Sales, general & administrative					52.5%	65.6%	49.0%
Total Non-GAAP Operating Expenses as a % of Revenue					**69.8%**	**79.9%**	**76.9%**

Data as of Q2 2022 earnings release on August 4, 2022. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.

NON-GAAP P&L TREND - CONSOLIDATED ($000's)

	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Revenue	**113,427**	**30,115**	**29,629**	**41,163**	**43,954**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**
Non-GAAP cost of sales	26,958	6,987	6,679	9,522	10,541	33,729	9,803	16,848	17,584	21,833	66,068	19,755	25,386
Non-GAAP gross profit	**86,469**	**23,128**	**22,950**	**31,641**	**33,413**	**111,132**	**34,318**	**45,401**	**45,296**	**52,129**	**177,144**	**51,178**	**58,765**
Non-GAAP Gross Margin	*76.2%*	*76.8%*	*77.5%*	*76.9%*	*76.0%*	*76.7%*	*77.8%*	*72.9%*	*72.0%*	*70.5%*	*72.8%*	*72.1%*	*69.7%*
Operating expenses (Non-GAAP):													
Research & development, Non-GAAP	14,153	3,779	3,689	4,480	4,723	16,671	5,303	7,175	7,951	7,530	27,959	8,750	9,234
Sales, general & administrative, Non-GAAP	90,313	24,512	22,569	31,479	35,523	114,083	36,545	49,909	52,490	58,669	197,613	60,515	65,276
Total operating expenses (Non-GAAP)	**104,466**	**28,291**	**26,258**	**35,959**	**40,246**	**130,754**	**41,848**	**57,084**	**60,441**	**66,199**	**225,572**	**69,265**	**74,510**
R&D as % of revenue	*12.5%*	*12.5%*	*12.5%*	*10.9%*	*10.7%*	*11.5%*	*12.0%*	*11.5%*	*12.6%*	*10.2%*	*11.5%*	*12.3%*	*11.0%*
SG&A as % of revenue	*79.6%*	*81.4%*	*76.2%*	*76.5%*	*80.8%*	*78.8%*	*82.8%*	*80.2%*	*83.5%*	*79.3%*	*81.3%*	*85.3%*	*77.6%*
Total OPEX as % of revenue	*92.1%*	*93.9%*	*88.6%*	*87.4%*	*91.6%*	*90.3%*	*94.8%*	*91.7%*	*96.1%*	*89.5%*	*92.7%*	*97.6%*	*88.5%*
Non-GAAP operating loss	**(17,997)**	**(5,163)**	**(3,308)**	**(4,318)**	**(6,833)**	**(19,622)**	**(7,530)**	**(11,683)**	**(15,145)**	**(14,070)**	**(48,428)**	**(18,087)**	**(15,745)**
Op loss as % of revenue	*-15.9%*	*-17.1%*	*-11.2%*	*-10.5%*	*-15.5%*	*-13.5%*	*-17.1%*	*-18.8%*	*-24.1%*	*-19.0%*	*-19.9%*	*-25.5%*	*-18.7%*
Less: Depreciation	6,775	2,014	2,161	2,307	2,704	9,186	3,409	5,068	5,311	6,544	20,332	7,085	7,506
Adjusted EBITDA	**(11,222)**	**(3,149)**	**(1,147)**	**(2,011)**	**(4,129)**	**(10,436)**	**(4,121)**	**(6,615)**	**(9,834)**	**(7,526)**	**(28,096)**	**(11,002)**	**(8,239)**
Adj EBITDA as % of revenue	*-9.9%*	*-10.5%*	*-3.9%*	*-4.9%*	*-9.4%*	*-7.2%*	*-9.3%*	*-10.6%*	*-15.6%*	*-10.2%*	*-11.6%*	*-15.5%*	*-9.8%*

REVENUE SUPPLEMENT

	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q121	Q221
Revenues:													
Products and services - Surgical	108,242	29,070	28,834	40,052	43,123	141,079	43,716	55,769	51,604	61,151	212,240	60,649	72,343
Products and services - Imaging	-	-	-	-	-	-	-	6,116	11,131	12,771	30,018	10,269	11,808
Revenue from products and services	108,242	29,070	28,834	40,052	43,123	141,079	43,716	61,885	62,735	73,922	242,258	70,918	84,151
Revenue from Int'l supply agreement	5,185	1,045	795	1,111	831	3,782	405	364	145	40	954	15	-
TOTAL REVENUE	**113,427**	**30,115**	**29,629**	**41,163**	**43,954**	**144,861**	**44,121**	**62,249**	**62,880**	**73,962**	**243,212**	**70,933**	**84,151**

YOY GROWTH %	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Products and services - Surgical	29.4%	0.0%	0.0%	0.0%	0.0%	30.3%	50.4%	93.4%	28.8%	41.8%	50.4%	38.7%	29.7%
Products and services - Imaging													93.1%
Revenue from products and services	29.4%	0.0%	0.0%	0.0%	0.0%	30.3%	50.4%	114.6%	56.6%	71.4%	71.7%	62.2%	36.0%
Revenue from Int'l supply agreement	-35.5%	0.0%	0.0%	0.0%	0.0%	-27.1%	-61.2%	-54.2%	-86.9%	-95.2%	-74.8%	-96.3%	-100.0%
TOTAL REVENUE	**23.7%**	**0.0%**	**0.0%**	**0.0%**	**0.0%**	**27.7%**	**46.5%**	**110.1%**	**52.8%**	**68.3%**	**67.9%**	**60.8%**	**35.2%**

PRODUCT CATEGORIES PER CASE	2019	Q120	Q220	Q320	Q420	2020	Q121	Q221	Q321	Q421	2021	Q122	Q222
Historical Product Categories per Case	1.6	1.7	1.8	1.8	1.9	1.8	1.9	2.0	2.0	2.0	2.0		
Product Categories per Case (inclusive of bulk orders)	1.7	1.8	1.9	1.9	2.0	1.9	2.0	2.1	2.1	2.1	2.1	2.1	2.2

Data as of Q2 2022 earnings release on August 4, 2022. ATEC cautions you that statements included in this document that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and growth outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; the Company's ability to compel surgeon adoption; and the Company's future ability to finance its operations and sufficiency of its cash runway. Important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; and the Company's ability to meet its financial obligations. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law. This document contains information regarding the Company's financial results that is calculated and presented on the basis of methodologies other than in accordance with accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing our financial results. Therefore, these measures should not be considered in isolation or as an alternative or superior to GAAP measures. Be aware that our presentation of these measures may not be comparable to similarly-titled measures used by other companies.